| ABSTRACT Objective: To investigate adverse reactions of bevacizumab in the treatment of malignant tumor and provide theoretic basis for clinical rational using bevacizumab. Methods:Totally 94 patients in our hospital using the bevacizumab during October 2016 to April 2018 were retrospectively analyzed. The age, gender, disease and the treatment of bevacizumab combination other chemotherapy drugs were statistics and analysis. Results:The primary disease were mainly colorectal cancer, non small cell lung cancer (NSSCLC) and breast cancer and so on, of which 53 cases were treated with first line chemotherapy and 41 cases were treated with second line chemotherapy. All adverse reaction occurred in 6 months, among which 64 cases occurred less than 3 months and 30 cases occurred within 3 to 5 months. The incidences of hemorrhage, anemia and were 29.79%, 29.79%, 25.53%, respectively, which were significantly higher than that in other adverse reactions (P<0.05). The incidences of specific clinical adverse reactions, such as hyperglycemia and enterobrosis were 7.45%, 1.06%. Conclusion:The probability of serious adverse reactions of bevacizumab is low. For high incidence or special ADR, the adverse reactions of bevacizumab should be regularly monitored and timely treated． |
